DVA - DaVita HealthCare posts Q2 earnings beat FY profit forecast raise

DaVita HealthCare Partners (NYSE:DVA) posted second-quarter results that beat Wall Street estimates, and raised its profit forecast for the year. The company's quarterly revenue increased more than 1% to $2.92B, beating analysts' estimate by $50M. 2021 Guidance: Adj. EPS of $8.80-$9.40 from prior guidance of $8.20-$9.00 vs. $8.66 consnesus. Adj. operating income of $1.8B-$1.87B vs. $1.75B in FY20; and FCF of $1B-$1.2B vs. $1.19B in FY20. Operating cash flow and free cash flow, both from continuing operations, were $680M and $503M, respectively. The company also reported quarterly profit of $2.64 per share. Chief executive officer Javier Rodriguez called the company's Q2 results "strong", and said that he "expect((s)) to see significant growth in our (the company's) integrated kidney care business over the next year." Shares up more than 5% post market. Previously (Aug. 3): DaVita HealthCare Partners EPS beats by $0.68, beats on revenue.

For further details see:

DaVita HealthCare posts Q2 earnings beat, FY profit forecast raise